Opexa Therapeutics (OPXA) Announces Issuance of 50th Patent for T-cell Immunotherapy Platform
8/27/2013 9:23:01 AM
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that several key patents have issued, further strengthening the Company's proprietary technology for the development of patient-specific immunotherapies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by